NCT07413939 2026-04-09
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
Clinical Trials
6 trialsNCT07518173 2026-04-08
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT05388500 2022-05-27
PHARE-C
Institut de cancérologie Strasbourg Europe
Phase 3 Not yet recruiting
NCT04158856 2019-11-12
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting